

## **LCT Global Files a Patent Application Over a Cannabinoid Combination Drug Candidate for Dementia**

### **Highlights:**

- LCT Global files a provisional patent application over a cannabinoid-based combination drug, known as AI-116, for the treatment of dementia
- LCT is in advanced discussions with a major Australian university over a research agreement to perform pre-clinical studies, including comparing the efficacy of AI-116 to existing registered drugs used to treat dementia
- The global dementia drugs market size was valued at more than US\$8.7B in 2021 and is projected to reach US\$19.7B by 2031 due to a global aging population.

Melbourne, Australia, 26 July 2023: Living Cell Technologies Limited ('LCT' or the 'Company') today announces that it has filed a new provisional patent application over a combination drug candidate, which includes cannabidiol ('CBD') and another off-patent pharmaceutical ingredient, and its use in the treatment of dementia.

The filing of a provisional patent application establishes the priority date of the invention ahead of potential competitor companies. The filing also marks the commencement of a second research and development (R&D) project for LCT.

The precursory development of the combination drug candidate, referred to as AI-116, has been overseen by the Company's scientific team and consultants. LCT is also in advanced discussions with a major Australian university to conduct pre-clinical studies to assess AI-116, including comparing the efficacy of AI-116 to an existing class of drugs used to treat dementia.

Dementia is a term used to describe a decline in cognitive function that affects a person's ability to perform daily activities. A person with dementia has two or more specific difficulties, including decline in memory, reasoning, language, coordination, mood and behaviour.

Causes of dementia include Alzheimer's disease, vascular dementia, lewy body dementia, frontotemporal dementia, Parkinson's disease and Huntington's disease. Alzheimer's disease is the most common cause of dementia and is characterized by the formation of amyloid plaques and tau tangles in the brain, leading to the progressive degeneration of brain cells and memory loss.

The primary focus of dementia treatment in recent decades has remained on managing symptoms and slowing the progression of the diseases underlying dementia. There has been no development of a cure for the diseases that cause dementia. The global dementia drugs market size was valued at more than US\$8.7B in 2021 and is projected to reach US\$19.7B by 2031, growing at a CAGR of 8.5% from 2022 to 2031<sup>1</sup>.

**This announcement has been approved for release to ASX by the LCT Board of Directors.**

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

### **Corporate and Media Enquiries**

Brad Dilkes

Non-executive Director

Mobile: +61 422 180 317

[brad@lctglobal.com](mailto:brad@lctglobal.com)

### **About Living Cell Technologies**

Living Cell Technologies Limited is a biotechnology company focused on discovering and developing novel treatments for debilitating neurological conditions, including dementia caused Alzheimer's disease, vascular dementia, lewy body dementia, frontotemporal dementia, Parkinson's disease and Huntington's disease. The Company is incorporated in Australia, with its operations based in Australia and New Zealand. LCT is listed on Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges.

The Company intends to seek shareholder approval to rename the Company to Algorae Pharmaceuticals Limited ('Algorae'). Algorae is a unique word over which the Company has lodged a pending trademark. It derives from the term algorithm, which underpins artificial intelligence. The revised business model of the Company incorporates the use of artificial intelligence to assist all drug discovery and development programs. The new name better reflects and represents the overall business of the Company as it works to expand into new research and development (R&D) programs in addition to the NTCELL research project. LCT will seek approval in a special resolution of shareholders to change the name of the Company to Algorae in the upcoming extraordinary meeting ('EGM') of shareholders that is planned for September 2023.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter or LinkedIn.

### **References**

<sup>1</sup> <https://www.alliedmarketresearch.com/dementia-drugs-market-A12014>

### **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Living Cell Technologies Limited

Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000

P: +61 422 180 317